Bundeswehr Institute of Microbiology, Neuherbergstrasse 11, D-80937 Munich, Germany.
J Antimicrob Chemother. 2012 Oct;67(10):2429-33. doi: 10.1093/jac/dks238. Epub 2012 Jul 4.
Tularaemia is a widespread zoonosis in Europe caused by Francisella tularensis subsp. holarctica. Because of a lack of standardized CLSI-approved antibiotic susceptibility data from European Francisella strains, the antibiotic susceptibilities of a selection of F. tularensis subsp. holarctica isolates originating from Germany, Austria, France, Spain and other European countries were determined. Rarely isolated species and subspecies of Francisella such as Francisella philomiragia, F. tularensis subsp. novicida and F. tularensis subsp. mediasiatica as well as the type strain of Francisella hispaniensis were included in this study.
MIC data were obtained using cation-adjusted Mueller-Hinton broth with a 2% growth supplement. The broth microdilution testing system comprised 14 antibiotics, including gentamicin, streptomycin, ciprofloxacin and tetracycline.
All of the 91 strains tested were susceptible to aminoglycosides, quinolones, tetracycline and chloramphenicol. The antimicrobial susceptibility of rare Francisellae was similar to the antibiotic profile of F. tularensis subsp. holarctica strains. For erythromycin, we detected two geographically distinct groups of F. tularensis subsp. holarctica isolates in western Europe. One group was resistant and the other one was susceptible. Both groups overlapped in a small region in Germany.
Being performed in accordance with CLSI criteria, this study provides reliable data on antibiotic susceptibility patterns of European Francisella isolates. The standardized methodology of this study can be used for testing of suspicious colonies from clinical specimens for therapeutic guidance. Based on the results, aminoglycosides or quinolones are recommended as first-choice antibiotics for the therapy of F. hispaniensis, F. philomiragia or F. tularensis subsp. novicida infections in immunocompromised patients.
土拉菌病是一种广泛存在于欧洲的动物源性疾病，由土拉弗朗西斯菌亚种 holarctica 引起。由于缺乏来自欧洲弗朗西斯菌属菌株的标准化 CLSI 批准的抗生素药敏数据，因此确定了源自德国、奥地利、法国、西班牙和其他欧洲国家的一批土拉弗朗西斯菌亚种 holarctica 分离株的抗生素敏感性。本研究还包括了弗朗西斯菌属的一些罕见分离种和亚种，如弗朗西斯菌 philomiragia、土拉弗朗西斯菌亚种 novicida 和土拉弗朗西斯菌亚种 mediasiatica 以及弗朗西斯菌 hispaniensis 的模式株。
使用含 2%生长补充剂的阳离子调整 Mueller-Hinton 肉汤获得 MIC 数据。肉汤微量稀释检测系统包含 14 种抗生素，包括庆大霉素、链霉素、环丙沙星和四环素。
测试的 91 株菌株均对氨基糖苷类、喹诺酮类、四环素类和氯霉素敏感。罕见弗朗西斯菌的抗菌药敏性与土拉弗朗西斯菌亚种 holarctica 菌株的抗生素谱相似。对于红霉素，我们在西欧检测到两个具有明显地域差异的土拉弗朗西斯菌亚种 holarctica 分离株群。一个群是耐药的，另一个群是敏感的。这两个群在德国的一个小区域内重叠。
本研究按照 CLSI 标准进行，提供了欧洲弗朗西斯菌属分离株抗生素敏感性模式的可靠数据。该研究的标准化方法可用于测试来自临床标本的可疑菌落，以指导治疗。根据结果，对于免疫功能低下患者的弗朗西斯菌 hispaniensis、弗朗西斯菌 philomiragia 或土拉弗朗西斯菌亚种 novicida 感染，建议使用氨基糖苷类或喹诺酮类作为首选抗生素。
